DALLAS, TX - SEPTEMBER 14: Republican presidential candidate Donald Trump speaks during a campaign rally at the American Airlines Center on September 14, 2015 in Dallas, Texas. More than 20,000 tickets have been distributed for the event. (Image: Getty)
President Donald Trump has earned capital gains from Regeneron Pharmaceuticals and Gilead Sciences Inc., the two biotechnology companies that have created drugs that are aiding Trump in his COVID-19 treatment. Since being diagnosed last week, Trump has been given an eight-gram dose of Regeneron’s antiviral cocktail and is on a five-day treatment of Gilead Science’s Remdesivir.
According to a 2017 financial disclosure form that was filed with the U.S. Office of Government Ethics, Trump had a capital gain of $50,001 to $100,000 for Regeneron Pharmaceuticals and $100,001 to $1 million for Gilead Sciences Inc.
Regeneron’s chief executive and a member of Trump’s golf club in Westchester County, New York, Dr. Leonard S. Schleifer, said Trump’s medical staff reached out to the company for permission to use the Regeneron’s REGN-COV2 cocktail drug, and the Food and Drug Administration cleared it.
It was unclear Saturday whether Trump currently has any direct stakes in Regeneron and Gilead.
Subscribe to our free weekly newsletter!
A week of political news in your in-box.
We find the news you need to know, so you don't have to.
A majority of Democrats joined Republicans in the House of Representatives to crush the bid…
Rep. Andy Ogles (R-Tennessee) said that New York City Democratic mayoral candidate Zohran Mamdani should…
On Tuesday, the Trump administration rescinded health guidance that the Biden administration established in 2022.…
Kilmar Abrego Garcia, a Maryland resident mistakenly deported to El Salvador in March, was returned…
On Friday, the Supreme Court ruled that lower courts can no longer grant nationwide injunctions,…
The Republican Party continues to fracture in President Donald Trump’s second term in the White…
